지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Background: This study was to determine the impact on the national healthcare expen-diture for the treatment of osteoporosis and fractures if the coverage period for osteo-porosis medication was extended from maximum a year to continuous period as re-quired. Methods: Preserving the current reimbursement guidelines, maximum one year’s coverage for osteoporosis medication was set as scenario A. Continuous coverage for patients who require medication was set as scenario B. As costs of medical service utili-zation are paid by the Korean National Health Insurance Program, all items were investi-gated and analyzed from the payer’s perspective. The combined treatment costs for os-teoporosis and osteoporotic fractures were assessed for each scenario. Results: Over five years the cost of osteoporosis medication in scenario A will increase from 184.3 billion KRW to 204.6 billion KRW. The cost of osteoporotic fracture treatment will increase from 1,037.3 billion KRW to 1,822.7 billion KRW. In scenario B, the cost of osteoporosis medi-cation will increase from 209.5 billion KRW to 388.1 KRW. The cost of osteoporotic frac-ture treatment will increase from 600.0 billion KRW to 1,054.3 billion KRW. The result showed savings of 2.50 trillion KRW cumulatively for five years when reimbursement cov-erage for osteoporosis treatments is extended from one year to as long as it’s clinically required. Conclusions: This study demonstrates that effective osteoporosis manage-ment through appropriate insurance coverage for osteoporosis medication should be considered not only for the patient’s viewpoint, but in terms of national insurance bud-get as well.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
Australian Government Department of Health and Ageing / / Pharmaceutical benefits scheme (PBS)
Black DM / 2000 / Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group / J Clin Endocrinol Metab 85 : 411
Borgstrom F / 2008 / Health economics of osteoporosis / Best Pract Res Clin Endocrinol Metab 22 : 885 ~ 900
Colon-Emeric C / 2000 / Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture / J Am Geriatr Soc 48 :
Health Insurance Review & Assessment Service / / Drug reimbursement criteria
Black DM / 2000 / Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group / J Clin Endocrinol Metab 85 : 411
Borgstrom F / 2008 / Health economics of osteoporosis / Best Pract Res Clin Endocrinol Metab 22 : 885 ~ 900
Colon-Emeric C / 2000 / Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture / J Am Geriatr Soc 48 :
Health Insurance Review & Assessment Service / / Drug reimbursement criteria
이 논문의 저자 정보
최근 본 자료
댓글(0)
0